Munish Sharma
Pulmonary Disease · Temple, TXNPI 1053703553
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 22 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 13 manufacturers, the largest accounting for just 18.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2020 at $261 and has fallen 71.3% since, to $75 in 2025. That places this record below the midpoint for pulmonary disease clinicians in TX, where the typical reported total is $1,976.
Across 22 payments — averaging $51.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$206
- Paratek Pharmaceuticals, Inc.$200
- United Therapeutics Corporation$122
- GSK$121
- Inari Medical, Inc.$116
- Johnson & Johnson$109
- plus $255 from 7 others
Across 7 payments — averaging $3866.00 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- GSK$27K
What the payments were for
- Food & beverage$1,129100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 2 | $206 |
| Paratek Pharmaceuticals, Inc. | 2 | $200 |
| United Therapeutics Corporation | 3 | $122 |
| GSK | 2 | $121 |
| Inari Medical, Inc. | 1 | $116 |
| Johnson & Johnson | 5 | $109 |
| La Jolla Pharmaceutical Company | 1 | $58 |
| Advanced Respiratory, Inc | 1 | $48 |
| E.r. Squibb & Sons, L.L.C. | 1 | $38 |
| Boston Scientific | 1 | $33 |
| EKOS Corporation | 1 | $28 |
| Mallinckrodt Hospital Products Inc. | 1 | $27 |
| Insmed, Inc. | 1 | $24 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FLOWTRIEVER CATHETER, S$116
- CT THROMBECTOMY SYSTEM KIT$116
- UPTRAVI$107
- NUZYRA$102
- TRELEGY ELLIPTA$102
How this compares
$1,129 in reported general payments places this provider in the 40th percentile of 904 pulmonary disease providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 28 | $772,521 |
| OpsumitMacitentan | 47 | $590,455 |
| AdempasRiociguat | 41 | $558,738 |
| Tyvaso DpiTreprostinil | 14 | $357,863 |
| OfevNintedanib Esylate | 19 | $237,121 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 223 | $170,900 |
| Ambrisentan | 19 | $68,948 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 90 | $60,498 |
| Spiriva RespimatTiotropium Bromide | 26 | $25,540 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 35 | $24,445 |
| Stiolto RespimatTiotropium Br/Olodaterol Hcl | 21 | $11,997 |
| Breo ElliptaFluticasone/Vilanterol | 24 | $11,538 |
| Sildenafil Citrate | 42 | $10,669 |
| EliquisApixaban | 11 | $8,157 |
| SymbicortBudesonide/Formoterol Fumarate | 27 | $7,648 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $206 | $1,362,97775 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Incruse Ellipta | $121 | $212,594296 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 904 pulmonary disease providers in Texas.
Other pulmonary disease in Temple
- Brian FurukawaTemple$148K
- Peter YauTemple$61K
- Antonio AnzuetoSan Antonio$1.8M
- Diego Maselli CaceresSan Antonio$1.5M
- Nicola HananiaHouston$1.3M
- Juan IribarrenBeaumont$915K
- William CalhounGalveston$568K
- David MarksSan Antonio$453K
- Sandeep SahayHouston$378K
- Jefy MathewThe Woodlands$318K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.